symbicort 160 mikrogramm/4,5 mikrogramm pro inhalation druckgasinhalation, suspension
astrazeneca gmbh (3079338) - budesonid; formoterolfumarat-dihydrat (ph.eur.); budesonid; formoterolfumarat-dihydrat (ph.eur.) - druckgasinhalation, suspension - budesonid (18667) 160 mikrogramm; formoterolfumarat-dihydrat (ph.eur.) (23761) 4,5 mikrogramm; budesonid (18667) 160 mikrogramm; formoterolfumarat-dihydrat (ph.eur.) (23761) 4,5 mikrogramm
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medikamente für obstruktive atemwegserkrankungen, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
flutiform
mundipharma gesellschaft mit beschränkter haftung - geschäftsanschrift - (3083021) - fluticason-17-propionat; formoterolfumarat-dihydrat (ph.eur.) - druckgasinhalation, suspension - teil 1 - druckgasinhalation, suspension; fluticason-17-propionat (23857) 0,05 milligramm; formoterolfumarat-dihydrat (ph.eur.) (23761) 0,005 milligramm
flutiform
mundipharma gesellschaft mit beschränkter haftung - geschäftsanschrift - (3083021) - fluticason-17-propionat; formoterolfumarat-dihydrat (ph.eur.) - druckgasinhalation, suspension - teil 1 - druckgasinhalation, suspension; fluticason-17-propionat (23857) 0,25 milligramm; formoterolfumarat-dihydrat (ph.eur.) (23761) 0,01 milligramm
duoresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medikamente für obstruktive atemwegserkrankungen, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
oxis turbuhaler 6 µg
eurimpharm arzneimittel gmbh (8050167) - formoterolfumarat-dihydrat (ph.eur.) - pulver zur inhalation - 6 µg - teil 1 - pulver zur inhalation; formoterolfumarat-dihydrat (ph.eur.) (23761) 6 mikrogramm
oxis turbuhaler 12µg
eurimpharm arzneimittel gmbh (8050167) - formoterolfumarat-dihydrat (ph.eur.) - pulver zur inhalation - 12 µg/dosis - teil 1 - pulver zur inhalation; formoterolfumarat-dihydrat (ph.eur.) (23761) 12 mikrogramm
oxis turbohaler 12 mikrogramm pulver zur inhalation
astrazeneca gmbh (3079338) - formoterolfumarat-dihydrat (ph.eur.) - pulver zur inhalation - teil 1 - pulver zur inhalation; formoterolfumarat-dihydrat (ph.eur.) (23761) 12 mikrogramm
oxis turbohaler 6 mikrogramm pulver zur inhalation
astrazeneca gmbh (3079338) - formoterolfumarat-dihydrat (ph.eur.) - pulver zur inhalation - teil 1 - pulver zur inhalation; formoterolfumarat-dihydrat (ph.eur.) (23761) 6 mikrogramm
inuvair nexthaler 200 µg/dose - 6 µg/dose pulver zur inhalation
chiesi - beclometasone dipropionate; formoterolfumarat-dihydrat - pulver zur inhalation - 200 µg/dose - 6 µg/dose - beclometasone dipropionate 200 µg/dose; formoterolfumarat-dihydrat 6 µg/dosis - formoterol and beclometasone